Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
Solventum Corp director Karen J. May exercised restricted stock units to acquire additional shares of common stock. On this date, 1,980 RSUs converted into 1,980 shares of common stock at a stated price of $0.00 per share. Each RSU represented a right to receive one share upon settlement, and the RSUs were fully vested. Following the transaction, May directly holds 5,544 shares of Solventum common stock, reflecting an exercise-and-hold move with no shares sold in this filing.
Solventum Corporation is asking shareholders to vote at its 2026 virtual annual meeting on May 15 on three items: electing four Class II directors, approving an advisory say‑on‑pay resolution, and ratifying PwC as independent auditor.
The proxy highlights Solventum’s first full year as a standalone MedTech company, with 2025 sales of $8.3B, diluted GAAP EPS of $8.88, diluted adjusted EPS of $6.11, reported sales growth of +0.9% and organic sales growth of +3.3%. MedSurg generated 58% of net sales, with Dental Solutions and Health Information Systems each at 16%.
Management underscores portfolio moves, including divesting the Purification & Filtration business to Thermo Fisher Scientific while retaining drinking water filtration, completing its first acquisition (Acera Surgical), and launching a share repurchase program. The Board emphasizes independent leadership with an independent Chair, majority voting for directors, phased declassification by 2028, and robust committee oversight of risk, strategy, talent, and science.
The compensation program is positioned as pay‑for‑performance, with 92% of CEO and 81% of other named executive officer target compensation at risk, heavily weighted to long‑term equity tied to multi‑year revenue, EPS and relative total shareholder return metrics. The Board reports broad 2025 shareholder outreach representing over 56% of outstanding shares (excluding 3M’s 14.7% stake) and cites adding relative TSR to performance share units in response to investor feedback.
Solventum Corp: Amendment to Schedule 13G/A by The Vanguard Group reporting zero beneficial ownership. The filing amends prior disclosures to reflect an internal realignment at The Vanguard Group, stating that certain subsidiaries now report separately in reliance on SEC Release No. 34-39538. The filing lists 0 shares and 0% ownership of Common Stock.
Solventum Corporation reported that Chief Accounting Officer Mary Wilcox has informed the company of her intent to retire and will resign from her role after a search for and appointment of her successor. This planned transition is framed as a retirement rather than an immediate or unexpected departure.
Solventum Corp director Wendell Amy McBride bought 1,475 shares of Common Stock in an open-market purchase. The transaction took place on 2026-03-10 at an average price of $68.03 per share. Following this transaction, her direct holdings increased to 5,039 shares of Solventum common stock.
Solventum Corp Chief Information Officer Amy Landucci reported equity compensation activity involving restricted stock units and common shares. On March 5, 2026, she was granted 12,716 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock upon settlement, vesting in three equal annual installments.
On March 6, 2026, 3,795 RSUs were converted into 3,795 shares of common stock, and 1,731 common shares at $69.41 per share were disposed of to cover tax obligations, described as a tax-withholding disposition. After these transactions, her directly held common stock position was 37,483 shares, with 7,593 RSUs remaining from the earlier award.
Solventum Corp Chief Supply Chain Officer Paul S. Harrington reported equity compensation activity and related tax withholding. On March 5, 2026, he was granted 10,950 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A common stock. These RSUs vest in three equal annual tranches on the first, second and third anniversaries of the grant date, subject to continued service. On March 6, 2026, 3,300 RSUs were exercised for 3,300 shares of common stock at a stated price of $0.00, and 1,073 shares of common stock were disposed of at $69.41 per share to cover tax obligations, leaving 18,170 common shares held directly.
Solventum Corp Chief Financial Officer Wayde D. McMillan reported several equity-related transactions. On March 5, 2026, he acquired 35,321 Restricted Stock Units (RSUs) as a grant, each representing a right to receive 1 share of Class A Common Stock. These RSUs vest in three equal annual tranches on the first, second and third anniversaries of the grant date, subject to continued service.
On March 6, 2026, he exercised 8,802 RSUs, converting them into 8,802 shares of Common Stock at a stated price of $0.00 per share. The filing also shows a disposition of 2,786 shares of Common Stock at $69.41 per share in a tax-withholding transaction to satisfy obligations arising from the equity award. After these transactions, his directly held Common Stock position was 43,538 shares, and his directly held RSUs totaled 35,321 units.
Solventum Corp Chief Human Resources Officer Tammy L. Gomez reported multiple equity compensation transactions. On March 5, 2026, she received a grant of 12,716 Restricted Stock Units (RSUs), each representing one share of Class A Common Stock. These RSUs vest in three equal annual installments on the first, second, and third anniversaries of the grant date, subject to continued service.
On March 6, 2026, 3,300 RSUs were exercised and converted into 3,300 shares of Common Stock at no cost, increasing her directly held Common Stock before withholding. To cover tax obligations, 895 Common shares were withheld at $69.41 per share, leaving her with 11,070 shares of Common Stock held directly after these transactions, and 6,603 RSUs remaining from earlier awards plus the new 12,716‑unit grant.
Solventum Corp Chief Executive Officer Bryan C. Hanson reported multiple equity transactions. On March 5, 2026, he acquired 105,963 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A common stock.
On March 6, 2026, he exercised RSUs covering 31,907 RSUs, receiving 31,907 shares of common stock, and then disposed of 10,395 shares of common stock at $69.41 per share to cover tax withholding. After these transactions, he directly held 123,910 shares of common stock and 105,963 RSUs. The new RSU grant vests in three equal annual tranches, subject to continued service.